Related Experiment Video
Updated: Dec 4, 2025
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Evolving trends in pancreatic cancer therapeutic development
Imani Bijou1,2, Jin Wang1,3
1Department of Pharmacology and Chemical Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX, USA.
Abstract:
Despite advances in translational research, the overall 5-year survival for pancreatic cancer remains dismal and with rising incidence pancreatic cancer is predicted to be the second leading cause of cancer death for many developed countries. Surgical intervention followed by cytotoxic chemotherapy are currently the best options for treatment, but disease recurrence is very common. Efforts to develop new therapeutic agents and delivery systems are necessary to achieve better clinical efficacy with less toxicity. Promising prospects are arising with new preclinical and clinical therapeutic strategies using small molecule targeted therapies, RNAi, stromal therapies, and immunotherapies. With a better understanding of the biology to aid target selection and discovery of biomarkers to aid precision medicine, better opportunities will evolve to shape the therapeutic landscape, enhance patient quality of life and increase overall survival.
Insights
Pancreatic cancer survival remains poor despite advances. New targeted therapies, RNAi, and immunotherapies offer promise for improved treatment efficacy and patient outcomes.
Area of Science:
- Oncology
- Translational Research
- Cancer Therapeutics
Background:
- Pancreatic cancer presents a dismal 5-year survival rate, with incidence rising globally.
- Current treatments (surgery, chemotherapy) often lead to disease recurrence.
- There is a critical need for novel therapeutic agents and delivery systems to improve efficacy and reduce toxicity.
Purpose of the Study:
- To review current and emerging therapeutic strategies for pancreatic cancer.
- To highlight the importance of understanding tumor biology and biomarkers for precision medicine.
- To discuss the potential of new approaches to improve patient survival and quality of life.
Main Methods:
- Review of preclinical and clinical studies on novel pancreatic cancer therapies.
- Analysis of emerging therapeutic modalities including targeted therapies, RNA interference (RNAi), stromal targeting, and immunotherapies.
- Exploration of the role of biomarkers in guiding precision medicine approaches.
Main Results:
- Small molecule targeted therapies show promise in preclinical and clinical settings.
- RNAi, stromal therapies, and immunotherapies represent emerging avenues for treatment.
- Advancements in understanding pancreatic cancer biology are crucial for identifying therapeutic targets and biomarkers.
Conclusions:
- New therapeutic strategies, including targeted therapies and immunotherapies, offer hope for improved pancreatic cancer treatment.
- Precision medicine, guided by biomarkers and a deeper understanding of cancer biology, will be key to future advancements.
- Continued research is essential to overcome treatment resistance and enhance patient survival and quality of life.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
02:56Treatment Resistant Cancers
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...